Drugs / NEUK203-13
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07366658 | Feb → Oct 2026 expected | small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEUK203-13 | “NEUK203-13 Injection is a chimeric antigen receptor (CAR)-natural killer (NK) cell therapy (CAR-NK) derived from induced pluripotent stem cells (iPSCs).” NCT07366658 ↗ |
| Action | Deplete | “enabling precise recognition and elimination of malignant/cancer cells expressing the specific antigen DLL3” NCT07366658 ↗ |
| Modality | Cell therapy | “a novel cell therapy called NEUK203-13 Injection” NCT07366658 ↗ |
| Route | Intravenous | “NEUK203-13 is administered via intravenous infusion” NCT07366658 ↗ |
| Target | DLL3 | “targeting the DLL3 protein highly expressed in SCLC or other neuroendocrine tumors(NETs)” NCT07366658 ↗ |